1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. SI-BONE, Inc.
  6. Summary
    SIBN   US8257041090

SI-BONE, INC.

(SIBN)
  Report
Real-time Estimate Cboe BZX  -  03:19 2022-08-19 pm EDT
18.15 USD   +0.11%
08/18INSIDER SELL : Si-bone
MT
08/09SI-BONE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
08/09Morgan Stanley Raises SI-Bone's Price Target to $21 From $18, Maintains Overweight Rating
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/15/2022 08/16/2022 08/17/2022 08/18/2022 08/19/2022 Date
17.18(c) 17.54(c) 17.4(c) 18.13(c) 18.16 Last
266 998 245 133 389 536 427 683 182 184 Volume
+2.87% +2.10% -0.80% +4.20% +0.17% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 107 M - -
Net income 2022 -65,5 M - -
Net cash position 2022 58,8 M - -
P/E ratio 2022 -9,33x
Yield 2022 -
Sales 2023 130 M - -
Net income 2023 -54,7 M - -
Net cash position 2023 30,3 M - -
P/E ratio 2023 -11,5x
Yield 2023 -
Capitalization 622 M 622 M -
EV / Sales 2022 5,25x
EV / Sales 2023 4,54x
Nbr of Employees 352
Free-Float 98,2%
More Financials
Company
SI-BONE, Inc. is a medical device company. The Company is focused on the development of implantable devices used in the surgical treatment of sacro-pelvic anatomy. Its invasive surgical implant system, iFuse, is used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. Its iFuse Implant System includes a series of triangular titanium implants and the... 
More about the company
Ratings of SI-BONE, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about SI-BONE, INC.
08/18INSIDER SELL : Si-bone
MT
08/09SI-BONE, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
08/09Morgan Stanley Raises SI-Bone's Price Target to $21 From $18, Maintains Overweight Rati..
MT
08/09Needham Adjusts SI-Bone's Price Target to $24 From $28, Reiterates Buy Rating
MT
08/08SI BONE : Reports Financial Results for the Second Quarter 2022 - Form 8-K
PU
08/08SI BONE : June 2022 Investor Presentation
PU
08/08SI-BONE : Q2 Earnings Snapshot
AQ
08/08TRANSCRIPT : SI-BONE, Inc., Q2 2022 Earnings Call, Aug 08, 2022
CI
08/08Earnings Flash (SIBN) SI-BONE Posts Q2 Revenue $25.6M
MT
08/08SI-BONE, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June..
CI
08/08SI-BONE, Inc. Reports Financial Results for the Second Quarter 2022
AQ
08/08SI-BONE, Inc. Provides Earnings Guidance for the Fiscal Year 2022
CI
07/18SI-BONE To Report Second Quarter 2022 Financial Results on August 8, 2022
AQ
07/18SI-BONE To Present at The Canaccord Genuity 42nd Annual Growth Conference 2022
AQ
07/15Morgan Stanley Lowers SI-Bone's Price Target to $18 From $22, Overweight Rating Kept
MT
More news
News in other languages on SI-BONE, INC.
08/18VENTE PAR UN INITIÉ : Si-bone
08/08Earnings Flash (SIBN) SI-BONE affiche un chiffre d'affaires de 25,6 millions de dollars..
08/08SI-BONE, Inc. annonce ses résultats pour le deuxième trimestre et le semestre clos le 3..
08/08SI-BONE, Inc. fournit des prévisions de bénéfices pour l'année fiscale 2022
06/13SI-Bone reçoit l'autorisation de la FDA pour l'indication élargie du système d'implants..
More news
Analyst Recommendations on SI-BONE, INC.
More recommendations
Chart SI-BONE, INC.
Duration : Period :
SI-BONE, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SI-BONE, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 18,13 $
Average target price 24,57 $
Spread / Average Target 35,5%
EPS Revisions
Managers and Directors
Laura A. Francis Chief Executive Officer & Director
Anshul Maheshwari Chief Financial & Accounting Officer
Jeffrey W. Dunn Executive Chairman
Scott A. Yerby Chief Technology Officer & Senior VP-Engineering
W. Carlton Reckling Vice President-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
SI-BONE, INC.-18.37%622
SHOCKWAVE MEDICAL, INC.66.42%10 662
MASIMO CORPORATION-45.38%8 401
NOVOCURE LIMITED6.57%8 380
PENUMBRA, INC.-41.81%6 335
GETINGE AB-44.42%5 724